Colgate-Palmolive Company: 2025 Annual Report (10-K) Summary
Business Context and Reporting Period
This summary covers the fiscal year ended December 31, 2025. Colgate-Palmolive Company operates globally in two primary segments: Oral, Personal and Home Care (77% of net sales) and Pet Nutrition (23% of net sales). The company markets products in over 200 countries, with approximately two-thirds of net sales generated outside the United States. The reporting period reflects the conclusion of the company's 2025 strategic plan and the initiation of a new three-year "Strategic Growth and Productivity Program" approved in July 2025.
Key Financial Metrics
| Metric (in millions, except per share) | 2025 | 2024 |
|---|---|---|
| Net Sales | $20,382 | $20,101 |
| Organic Sales Growth | 1.4% | 7.4% |
| Gross Profit | $12,251 | $12,161 |
| Gross Margin | 60.1% | 60.5% |
| Operating Profit | $3,306 | $4,268 |
| Operating Margin | 16.2% | 21.2% |
| Net Income (Attributable to Colgate) | $2,132 | $2,889 |
| Diluted EPS | $2.63 | $3.51 |
| Free Cash Flow (Operating Cash Flow) | $4,198 | $4,107 |
| Total Debt | $7,988 | $7,949 |
| Cash and Cash Equivalents | $1,288 | $1,096 |
Material Changes vs. Prior Period
- Revenue: Net sales increased 1.4% to $20.4 billion, driven by net selling price increases of 2.1%, partially offset by volume declines of 0.4% and negative foreign exchange impacts of 0.3%.
- Profitability: GAAP operating profit decreased 23% to $3.3 billion. This decline was primarily due to a $919 million non-cash impairment charge related to goodwill and intangible assets in the skin health business (primarily Filorga), a $99 million charge related to an ERISA litigation matter, and acquisition-related costs.
- Non-GAAP Performance: Excluding the impairment, litigation, and restructuring charges, non-GAAP operating profit remained relatively flat at $4.347 billion (down 0.1% from 2024), and non-GAAP diluted EPS increased 3% to $3.69.
- Margins: Gross margin decreased 40 basis points to 60.1% due to significantly higher raw and packaging material costs (420 bps impact), partially offset by cost savings from funding-the-growth initiatives and higher pricing.
- Acquisitions: The company acquired Prime100 (a fresh pet food business in Australia) for approximately $301 million in April 2025.
Guidance, Outlook, and Risks
- Outlook: Management expects global macroeconomic and geopolitical conditions to remain challenging in 2026, citing inflation, high interest rates, and foreign currency volatility. The company anticipates continued softness across categories and potential shifts in consumer purchasing toward lower-priced or private label offerings.
- Strategic Initiatives: The new "Strategic Growth and Productivity Program" is estimated to result in cumulative pre-tax charges of $200 million to $300 million, with substantially all charges incurred by December 31, 2028. The program aims to optimize the supply chain and reduce overhead costs.
- Capital Allocation: The company continues to prioritize returning cash to shareholders. A new $5 billion share repurchase program was authorized in March 2025. Dividends were increased to $0.52 per share in Q2 2025.
- Risks: Key risks include geopolitical tensions (Ukraine, Middle East, Venezuela), trade policy changes and tariffs, volatility in raw material costs, and the impact of AI and changing retail landscapes on competition. The company also faces ongoing legal proceedings regarding talcum powder and tax matters in Brazil.
Investor Verification Checklist
- Impairment Details: Verify the specific assumptions used in the $919 million goodwill and intangible asset impairment test for the skin health reporting unit (Filorga), particularly regarding future cash flows and growth rates in China.
- ERISA Litigation Settlement: Confirm the final cash impact of the ERISA settlement ($332 million total, with $99 million in legal fees paid by the company) and its effect on future pension funding requirements.
- Raw Material Costs: Monitor the trajectory of raw material and packaging costs, which significantly pressured gross margins in 2025, and the effectiveness of price increases in offsetting these costs.
- Productivity Program Execution: Track the realization of cost savings from the new "Strategic Growth and Productivity Program" against the estimated $200-$300 million in charges.
- Geopolitical Exposure: Assess the ongoing impact of trade tariffs and geopolitical instability on operations in Latin America, Asia Pacific, and the Eurasia region.